CMS would let off-label use trigger new price talks

A medicine that finds a new off-label use could get pulled back into Medicare price talks under a proposal from CMS. Off-label use means a drug is prescribed for a condition, patient group or dose that the Food and Drug Administration has not specifically approved. Under the new rule, that later use could help determine whether a selected drug stays in, or comes back into, the Medicare Drug Price Negotiation Program, beginning in 2029.

The agency would also line up that off-label review with the same initial offer process it uses when negotiations begin. That matters because it gives CMS one standard for judging a drug’s changing profile instead of treating the later evidence as a separate afterthought.

When a second use changes the stakes

CMS says a primary manufacturer of a selected drug could voluntarily submit information about a new indication, or other new information tied to the factors the agency considers under the statute. In plain terms, that means a drug maker would have a way to tell Medicare that a medicine’s medical life has changed since it first entered the program.

For manufacturers, that cuts both ways. A new off-label use can expand a drug’s reach and its value, but it can also give Medicare another basis to revisit pricing pressure. For beneficiaries, the change could matter when a drug becomes important for a wider set of patients after it was first singled out for negotiation.

Why 2029 matters

The timing is built into the proposal. CMS would not apply the new off-label framework immediately; it would start in 2029, alongside the broader Medicare Drug Price Negotiation Program update that the agency is writing now.

That puts a new kind of significance on clinical drift, the way a drug’s real-world use can widen after approval. In earlier eras, that sort of change might have stayed mostly inside medical journals and specialist offices. Here, it could end up back on the price-setting table.